Global Male Infertility Drug Pipeline Landscape Report 2021 -

DUBLIN--()--The "Male Infertility (Women's and Male Health) - Drugs In Development, 2021" report has been added to's offering.

Male Infertility - Drugs In Development, 2021, provides an overview of the Male Infertility (Male Health) pipeline landscape.

Male infertility refers to a male's inability to achieve a pregnancy in a fertile female. Male infertility is caused due to low sperm production, immobile sperm, or blockages that prevent the delivery of sperm.

Symptoms include pain, swelling or a lump in the testicle area. Predisposing factors include smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes surgery and hormone replacement therapy.

Report Highlights

Male Infertility - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Male Infertility (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Male Infertility (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Male Infertility (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:


Male Infertility - Overview

  • Male Infertility - Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Male Infertility - Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Male Infertility - Companies Involved in Therapeutics Development

  • Aprilbio Co Ltd
  • cStem Regeneration Pharmaceutical Co Ltd
  • Igyxos SA
  • Park Active Molecules
  • Prokrea BCN SL
  • Reven Pharmaceuticals Inc
  • St George Street Capital Ltd

Male Infertility - Drug Profiles

  • ASCP-05
  • Drug for Male Infertility
  • follicle stimulating hormone biobetter
  • FSH-01
  • Gene Therapy to Activate AR for Male Infertility
  • Monoclonal Antibody for Men and Women Infertility
  • PAM-8
  • pentoxifylline
  • Recombinant Beta Glucosidase 2 Replacement for Gaucher's Disease and Male Infertility
  • RPOT-1005a
  • Small Molecule to Activate Telomerase for Men Infertility and Women Infertility
  • trequinsin

Male Infertility - Dormant Projects


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900